CDK1 and colorectal carcinoma: For instance, in colorectal carcinoma (CRC) with the BRAF V600E mutation (8% of CRC cases), treatment with CDK1 inhibitors significantly enhances the therapeutic efficacy of MEK inhibitors by reactivating caspase 8 activity.301